Tetanus - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 76 pages report, published by Global Markets Direct

Keywords : Tetanus Therapeutic Products under Development, Key Players in Tetanus Therapeutics, Tetanus Pipeline Overview, Tetanus Pipeline, Tetanus Pipeline Assessment

Report ThumbnailSeptember-2013
Tetanus - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Tetanus - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Tetanus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tetanus. Tetanus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Tetanus.
- A review of the Tetanus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Tetanus pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Tetanus.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Tetanus, H2 2013 9
  • Products under Development for Tetanus - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Products under Investigation by Universities/Institutes, H2 2013 13
  • Late Stage Products, H2 2013 14
  • Mid Clinical Stage Products, H2 2013 15
  • Early Clinical Stage Products, H2 2013 16
  • Discovery and Pre-Clinical Stage Products, H2 2013 17
  • Assessment by Monotherapy Products, H2 2013 35
  • Assessment by Combination Products, H2 2013 36
  • Assessment by Route of Administration, H2 2013 37
  • Assessment by Stage and Route of Administration, H2 2013 38
  • Assessment by Molecule Type, H2 2013 39
  • Assessment by Stage and Molecule Type, H2 2013 40
  • List of Tables
  • Number of Products Under Development for Tetanus, H2 2013 9
  • Products under Development for Tetanus - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Number of Products under Investigation by Universities/Institutes, H2 2013 13
  • Comparative Analysis by Late Stage Development, H2 2013 14
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 16
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
  • Products under Development by Companies, H2 2013 18
  • Products under Investigation by Universities/Institutes, H2 2013 19
  • Sanofi-Aventis, H2 2013 20
  • GlaxoSmithKline plc, H2 2013 21
  • Takeda Pharmaceutical Company Limited, H2 2013 22
  • Biological E. Limited, H2 2013 23
  • Zosano Pharma, Inc., H2 2013 24
  • Green Cross Corporation, H2 2013 25
  • LG Life Sciences, Ltd, H2 2013 26
  • Panacea Biotec Limited, H2 2013 27
  • Bharat Biotech International Limited, H2 2013 28
  • Vaxin, Inc., H2 2013 29
  • Sinovac Biotech Co., Ltd., H2 2013 30
  • iBio, Inc., H2 2013 31
  • Serum Institute of India Limited, H2 2013 32
  • Indian Immunologicals Limited, H2 2013 33
  • Beijing Minhai Biotechnology Co., Ltd, H2 2013 34
  • Assessment by Monotherapy Products, H2 2013 35
  • Assessment by Combination Products, H2 2013 36
  • Assessment by Stage and Route of Administration, H2 2013 38
  • Assessment by Stage and Molecule Type, H2 2013 40
  • Tetanus Therapeutics - Drug Profile Updates 65
  • Tetanus Therapeutics - Dormant Products 68
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Tetanus Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Tetanus 9
  • Tetanus Therapeutics under Development by Companies 11
  • Tetanus Therapeutics under Investigation by Universities/Institutes 13
  • Late Stage Products 14
  • Comparative Analysis 14
  • Mid Clinical Stage Products 15
  • Comparative Analysis 15
  • Early Clinical Stage Products 16
  • Comparative Analysis 16
  • Discovery and Pre-Clinical Stage Products 17
  • Comparative Analysis 17
  • Tetanus Therapeutics - Products under Development by Companies 18
  • Tetanus Therapeutics - Products under Investigation by Universities/Institutes 19
  • Companies Involved in Tetanus Therapeutics Development 20
  • Sanofi-Aventis 20
  • GlaxoSmithKline plc 21
  • Takeda Pharmaceutical Company Limited 22
  • Biological E. Limited 23
  • Zosano Pharma, Inc. 24
  • Green Cross Corporation 25
  • LG Life Sciences, Ltd 26
  • Panacea Biotec Limited 27
  • Bharat Biotech International Limited 28
  • Vaxin, Inc. 29
  • Sinovac Biotech Co., Ltd. 30
  • iBio, Inc. 31
  • Serum Institute of India Limited 32
  • Indian Immunologicals Limited 33
  • Beijing Minhai Biotechnology Co., Ltd 34
  • Tetanus - Therapeutics Assessment 35
  • Assessment by Monotherapy Products 35
  • Assessment by Combination Products 36
  • Assessment by Route of Administration 37
  • Assessment by Molecule Type 39
  • Drug Profiles 41
  • Act-HIB reconstituted with TRIPACEL - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • GSK-217744 - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • DTP-HepB-Polio-Hib - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • DTaP-HepB - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • DtwP-HB-Hib (liq) Vaccine - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • LBVF-0101 - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • DTwP-HepB Vaccine - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • TAK-361S - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • component pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • Tetanus Vaccine - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • Tetanus Vaccine - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • Tetanus Vaccine - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • DTwP-HBV-Hib - Drug Profile 56
  • Product Description 56
  • Mechanism of Action 56
  • R&D Progress 56
  • GC-3111A - Drug Profile 57
  • Product Description 57
  • Mechanism of Action 57
  • R&D Progress 57
  • DTwP-IPV - Drug Profile 58
  • Product Description 58
  • Mechanism of Action 58
  • R&D Progress 58
  • LBVP-0101 - Drug Profile 59
  • Product Description 59
  • Mechanism of Action 59
  • R&D Progress 59
  • Pentavalent DTwP-Hib-IPV Vaccine - Drug Profile 60
  • Product Description 60
  • Mechanism of Action 60
  • R&D Progress 60
  • DTaP Vaccine - Drug Profile 61
  • Product Description 61
  • Mechanism of Action 61
  • R&D Progress 61
  • Diphtheria Tetanus Pertussis Low Vaccine - Drug Profile 62
  • Product Description 62
  • Mechanism of Action 62
  • R&D Progress 62
  • Diphtheria Tetanus Acellular Pertussis Vaccine - Drug Profile 63
  • Product Description 63
  • Mechanism of Action 63
  • R&D Progress 63
  • Diphtheria Tetanus Acellular Pertussis Vaccine - Drug Profile 64
  • Product Description 64
  • Mechanism of Action 64
  • R&D Progress 64
  • Tetanus Therapeutics - Drug Profile Updates 65
  • Tetanus Therapeutics - Dormant Products 68
  • Tetanus - Product Development Milestones 69
  • Featured News & Press Releases 69
  • Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 69
  • Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 69
  • Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 69
  • Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 70
  • Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 71
  • Jan 30, 2008: GlaxoSmithKline Launches Two New Innovative Vaccines 71
  • Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 72
  • Jun 13, 2005: U.S. FDA Licenses sanofi pasteur’s ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 72
  • Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 73
  • Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 73
  • Appendix 75
  • Methodology 75
  • Coverage 75
  • Secondary Research 75
  • Primary Research 75
  • Expert Panel Validation 75
  • Contact Us 76
  • Disclaimer 76

Please select a license type

Share

Related Products

Global Markets DirectTetanus - Pipeline Review, H2 2013Product ThumbnailTetanus - Pipeline Review, H2 2013, Industry ReportProduct #: 113288
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved